Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF Induction vs PF Adjuvant Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma
NCT03574324Phase 3Unknown
- Sponsor
- Guizhou Medical University
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Guizhou Medical University. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
docetaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03574324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574324.